Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2012 Oct;34(3):397-403.
doi: 10.1007/s11239-012-0764-0.

Impact of smoking status on outcome in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention

Tomasz Rakowski  1 , Zbigniew Siudak, Artur Dziewierz, Jacek S Dubiel, Dariusz Dudek
Affiliations
Clinical Trial

Impact of smoking status on outcome in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention

Tomasz Rakowski et al. J Thromb Thrombolysis. 2012 Oct.

Abstract

There are some data showing lower mortality of smokers comparing to non-smokers in patients with ST-segment elevation myocardial infarction (STEMI) when treated with thrombolysis or without reperfusion therapy. However, the role of smoking status is less established in patients with STEMI undergoing mechanical reperfusion. We evaluate the influence of smoking on outcome in patients with STEMI treated with primary percutaneous coronary intervention (PCI). A total of 1,086 patients enrolled into EUROTRANSFER Registry were included into present analysis. Patients were divided according to smoking status during STEMI presentation into those who were current smokers (391 patients, 36 %) and non-smokers (695 patients, 64 %). Current smokers were younger and more often men and less frequently had high-risk features as previous myocardial infarction, history of chronic renal failure, previous PCI, diabetes mellitus, anterior wall STEMI, and multivessel disease. Unadjusted mortality at 1 year was lower in current smokers comparing to non-smokers (3.3 vs. 9.5 %; OR 0.33 CI 0.18-0.6; p = 0.0001). However, after adjustment for age and gender by logistic regression, there was no longer significant difference between groups (OR 0.7; CI 0.37-1.36; p = 0.30). In conclusion, current smokers with STEMI treated with primary PCI have lower mortality at 1 year comparing to non-smokers, but this result may be explained by differences in baseline characteristics and not by smoking status itself. Current smokers developed STEMI more than 10 years earlier than non-smokers with similar age and sex-adjusted risk of death at 1 year. These results emphasize the role of efforts to encourage smoking cessation as prevention of myocardial infarction.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Distribution of patients according to age and smoking status. TIMI Risk Score (TIMI RS) presented as median and inter-quartile range. Insignificant differences in TIMI RS between current smokers and non-smokers (p > 0.2)
Fig. 2
Fig. 2
Kaplan–Meier survival curves for 1 year follow-up
Fig. 3
Fig. 3
Mortality at 30 day (a) and 1 year (b) in predefined age groups
See this image and copyright information in PMC

References

    1. Doll R, Peto R. Mortality in relation to smoking: 20 years’ observations on male British doctors. BMJ. 1976;2:1525–1536. doi: 10.1136/bmj.2.6051.1525. - DOI - PMC - PubMed
    1. Wilhelmsson C, Vedin JA, Elmfeldt D, et al. Smoking and myocardial infarction. Lancet. 1975;1:415–420. doi: 10.1016/S0140-6736(75)91488-9. - DOI - PubMed
    1. Kannel WB, Higgins M. Smoking and hypertension as predictors of cardiovascular risk in population studies. J Hypertens Suppl. 1990;8:S3–S8. - PubMed
    1. Barbash GI, White HD, Modan M, et al. Significance of smoking in patients receiving thrombolytic therapy for acute myocardial infarction. Experience gleaned from the International Tissue Plasminogen Activator/Streptokinase Mortality Trial. Circulation. 1993;87:53–58. doi: 10.1161/01.CIR.87.1.53. - DOI - PubMed
    1. Barbash GI, Reiner J, White HD, et al. Evaluation of paradoxic beneficial effects of smoking in patients receiving thrombolytic therapy for acute myocardial infarction: mechanism of the “smoker’s paradox” from the GUSTO-I trial, with angiographic insights. Global Utilization of Streptokinase and Tissue-Plasminogen Activator for Occluded Coronary Arteries. J Am Coll Cardiol. 1995;26:1222–1229. doi: 10.1016/0735-1097(95)00299-5. - DOI - PubMed